Olanzapine Dosing for Mood Disorders with Agitation
For acute agitation in adults with mood disorders (bipolar mania), use intramuscular olanzapine 10 mg as the initial dose, with the option to reduce to 5-7.5 mg when clinically warranted; subsequent doses up to 10 mg may be given 2-4 hours apart, with a maximum of 3 doses (30 mg total) in 24 hours. 1
Route-Specific Dosing
Intramuscular Administration (Preferred for Acute Agitation)
- Initial dose: 10 mg IM
- Lower doses (5 or 7.5 mg): Consider for elderly, debilitated patients, or those predisposed to hypotension 1
- Repeat dosing: Up to 10 mg may be given 2-4 hours after initial dose, then 4 hours after second dose
- Maximum: 3 doses (30 mg total) in 24 hours 1
Critical safety measure: Assess for orthostatic hypotension before each subsequent dose. Do not administer additional doses if clinically significant postural blood pressure changes occur 1.
IM olanzapine demonstrates superior efficacy to placebo at 2 hours and 24 hours post-injection, with comparable safety to lorazepam but fewer extrapyramidal symptoms than haloperidol 2, 3. In head-to-head trials, IM olanzapine (10 mg) significantly outperformed both lorazepam (2 mg) and placebo in reducing agitation scores within 2 hours 2.
Oral Administration (Transition or Less Severe Agitation)
Once acute agitation is controlled, transition to oral olanzapine:
- Starting dose: 10-15 mg once daily for bipolar mania 1
- Dose range: 5-20 mg/day (FDA-approved range) 1
- Timing: Can be given without regard to meals 1
Higher-Dose Strategies (Off-Label)
For severely agitated patients requiring more aggressive management, evidence supports rapid initial dose escalation (RIDE):
- Days 1-2: Up to 40 mg/day oral olanzapine
- Days 3-4: Up to 30 mg/day
- Maintenance: 5-20 mg/day thereafter 4
This RIDE strategy demonstrated superior efficacy compared to standard dosing (10 mg/day plus lorazepam) at 24 hours, with no clinically significant differences in safety or oversedation 4. An observational study of 166 severely agitated patients with aggression used an average daily dose of 21.2 mg, achieving 64.2% remission of agitation by day 5 5.
Important caveat: Doses above 20 mg/day are off-label and carry increased risk of weight gain and elevated prolactin 6. Reserve higher doses for treatment-resistant patients with severe, persistent symptoms.
Clinical Considerations
When to Choose Olanzapine
Olanzapine offers advantages over conventional antipsychotics:
- Lower rates of extrapyramidal symptoms and dystonia compared to haloperidol 2, 3
- Minimal QTc prolongation (least among antipsychotics studied) 7
- Effective for both schizophrenia-related and bipolar-related agitation 1, 2
Safety Monitoring
- Orthostatic hypotension: Most critical concern with IM dosing, especially with maximal dosing (3 doses of 10 mg) 1
- Respiratory depression: Low risk (2.4% hypoxia in pediatric study) 8
- Dystonia: Rare (0.35% in one large series) 8
Geriatric Patients
Use 5 mg IM as initial dose in elderly patients, with consideration for 2.5 mg in debilitated individuals 1. Note that a 2025 geriatric guideline found quetiapine had the lowest adverse event rate among antipsychotics in older adults, though this was for oral administration 9.
Combination Therapy
Benzodiazepines may be added but are not necessary—olanzapine monotherapy is effective 4, 5. One study found no significant difference in PANSS-EC reduction with or without concurrent benzodiazepine use 5.
Transition to Maintenance
Once agitation is controlled with IM olanzapine, initiate oral therapy at 5-20 mg/day as soon as clinically appropriate 1. For bipolar disorder maintenance, continue at the lowest effective dose (typically 5-20 mg/day) with periodic reassessment 1.